RESUMO
The current medical treatments of androgenetic alopecia (AGA) have hardly achieved a satisfying clinical improvement. Biologic regenerative therapies, such as platelet-rich plasma (PRP) injections in the scalp, have been proposed recently. This multidisciplinary prospective study aims to explore the efficacy and safety of autologous PRP injections into the scalp of patients with AGA. Fifty-four patients with AGA (35 men and 19 women) were enrolled. Non-activated autologous PRP was injected into the androgen-related areas of the scalp. The study protocol consisted of three sessions of injections at 3-month interval. The effects were assessed by means of noninvasive methods. Safety profile, patient satisfaction, and Dermatology Life Quality Index were assessed. Increase in hair thickness was observed 1 month after the first PRP injection, and hair loss reduction was found after 3 months. In most patients, the improvement was progressively evident until the 12th month. Hair growth/production showed differences between women and men. The safety profile was satisfactory. This study confirms that PRP injections are effective in reducing thinning of the scalp hair and suggests more efficacy in women.
Assuntos
Alopecia , Plasma Rico em Plaquetas , Alopecia/terapia , Feminino , Cabelo , Humanos , Masculino , Estudos Prospectivos , Couro Cabeludo , Resultado do TratamentoRESUMO
[This corrects the article DOI: 10.1155/2017/2079068.].
RESUMO
The authors present a case of an 80-year-old Caucasian male with multiple gastric and rectal metastases from malignant melanoma presenting with hypochromic anemia as the sole symptom of disease without evidence of cutaneous and ocular tumor localization. The patient had a medical history positive for malignant lentigo melanoma of the occipital region of the scalp and early stage laryngeal squamous cell carcinoma and prostatic carcinoma treated with radiation therapy. The authors make some considerations on intestinal involvement by metastatic melanoma and discuss the choice of not treating with endoscopic procedures the gastric metastatic lesions most likely responsible for the clinical sign present at diagnosis. The patient was referred to clinical oncologists and received immunotherapy with ipilimumab and pembrolizumab.